Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Vyne Therapeutics Inc VYNE

Healthcare
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VYNE)

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire March 19, 2024

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

GlobeNewswire February 29, 2024

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

GlobeNewswire February 27, 2024

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 21, 2024

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

GlobeNewswire January 10, 2024

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

GlobeNewswire January 3, 2024

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 13, 2023

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

GlobeNewswire November 7, 2023

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

GlobeNewswire November 1, 2023
View More News ››

Opinion & Analysis (NDAQ:VYNE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VYNE)

VYNE......no volume

Just a big "nothing burger"
Iseneschal - February 15, 2023

VYNE...... NR

On watch at $4 No position
Iseneschal - February 15, 2023
View more Bullboard ››

Western Exploration Inc

Western Exploration Inc

Western Exploration Inc. is focused on gold and silver discoveries in Northern Nevada. The Company is engaged in the business ...
View More »